-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2022, due to the influence of the medical environment, personnel changes in the industry are still frequent
.
According to incomplete statistics, at least 20 senior executives of domestic pharmaceutical companies have changed, and many of the positions that have changed are chairman, vice president, deputy general manager, core technicians, etc.
, involving Xinlitai, Guangshengtang, Xinhua Medical.
.
.
For example, on February 23, Guangshengtang announced that the company recently appointed George Zhang (Zhang Yuhua) as the company's innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
(hereinafter referred to as "Guangsheng Zhonglin").
) general manager, responsible for the operation and management of Guangsheng Zhonglin innovative drugs
.
According to the data, Dr.
Zhang has published more than 30 research papers in international journals such as "Nature" and "Cell"; he is responsible for advancing 7 new drug candidates into clinical trials; he has participated in and led the development of 6 new drugs in the United States, Europe and Canada.
Application and listing; rich experience in innovative drug research and development, product pipeline layout and expansion
.
On February 23, Xinhua Medical issued an announcement stating that due to job transfer, Mr.
Zhao Jun applied for his resignation as an employee representative director, and the trade union committee of the company's employee representative congress elected Mr.
Cui Hongtao as the company's employee representative director
.
Mr.
Cui Hongtao was changed from director to employee representative director
.
On February 21, Nuotai Biological announced that Ding Jiansheng, the company's core technical staff, had recently resigned due to personal reasons and would no longer hold any positions in the company after his resignation
.
On February 17, Botuo Bio announced that Mr.
Ye Chunsheng, the supervisor, applied for his resignation as a non-employee supervisor of the company due to work arrangements
.
After resigning as a non-employee supervisor, Mr.
Ye Chunsheng still holds other positions in the company
.
At the same time, the company held the tenth meeting of the second board of supervisors.
The meeting reviewed and approved the "Proposal on the Resignation of Supervisors of the Company and By-election of Supervisors", and nominated Ms.
Zhao Danyun as the candidate for the non-employee representative supervisor of the second board of supervisors of the company.
From the date of deliberation and approval at the company's general meeting of shareholders to the date of the expiration of the second session of the Supervisory Committee
.
On February 11, BeiGene announced that Dr.
Ben Yong, the company's core technical staff, has applied for resignation to the company in August 2021, and he will no longer serve as the company's immuno-oncologist from February 9, 2022 (US local time).
Chief Medical Officer jobs
.
Dr.
Yong Ben will continue to serve as a special advisor to the company's global head of R&D to assist in a smooth transition of the new Chief Medical Officer of Immuno-Oncology during the initial period of his appointment until June 30, 2022
.
On February 7, Xinlitai announced that the company recently received a written resignation report submitted by Zhu Meixia, the company's deputy general manager
.
Zhu Meixia applied to resign from the position of deputy general manager of the company because she had reached the retirement age
.
After the resignation takes effect, he will no longer hold any position in the company
.
.
.
.
The above is just a list of some pharmaceutical companies that have undergone personnel changes since February, but on the whole, a large number of pharmaceutical companies in the industry are currently announcing personnel adjustment plans under pressure from various aspects, reducing non-core business personnel, in order to save development funds, Adjust the development strategy
.
The analysis believes that this is the case for large pharmaceutical companies, and the funds of small pharmaceutical companies are more tight, so personnel reduction may be more frequent in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to incomplete statistics, at least 20 senior executives of domestic pharmaceutical companies have changed, and many of the positions that have changed are chairman, vice president, deputy general manager, core technicians, etc.
, involving Xinlitai, Guangshengtang, Xinhua Medical.
.
.
For example, on February 23, Guangshengtang announced that the company recently appointed George Zhang (Zhang Yuhua) as the company's innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co.
, Ltd.
(hereinafter referred to as "Guangsheng Zhonglin").
) general manager, responsible for the operation and management of Guangsheng Zhonglin innovative drugs
.
According to the data, Dr.
Zhang has published more than 30 research papers in international journals such as "Nature" and "Cell"; he is responsible for advancing 7 new drug candidates into clinical trials; he has participated in and led the development of 6 new drugs in the United States, Europe and Canada.
Application and listing; rich experience in innovative drug research and development, product pipeline layout and expansion
.
On February 23, Xinhua Medical issued an announcement stating that due to job transfer, Mr.
Zhao Jun applied for his resignation as an employee representative director, and the trade union committee of the company's employee representative congress elected Mr.
Cui Hongtao as the company's employee representative director
.
Mr.
Cui Hongtao was changed from director to employee representative director
.
On February 21, Nuotai Biological announced that Ding Jiansheng, the company's core technical staff, had recently resigned due to personal reasons and would no longer hold any positions in the company after his resignation
.
On February 17, Botuo Bio announced that Mr.
Ye Chunsheng, the supervisor, applied for his resignation as a non-employee supervisor of the company due to work arrangements
.
After resigning as a non-employee supervisor, Mr.
Ye Chunsheng still holds other positions in the company
.
At the same time, the company held the tenth meeting of the second board of supervisors.
The meeting reviewed and approved the "Proposal on the Resignation of Supervisors of the Company and By-election of Supervisors", and nominated Ms.
Zhao Danyun as the candidate for the non-employee representative supervisor of the second board of supervisors of the company.
From the date of deliberation and approval at the company's general meeting of shareholders to the date of the expiration of the second session of the Supervisory Committee
.
On February 11, BeiGene announced that Dr.
Ben Yong, the company's core technical staff, has applied for resignation to the company in August 2021, and he will no longer serve as the company's immuno-oncologist from February 9, 2022 (US local time).
Chief Medical Officer jobs
.
Dr.
Yong Ben will continue to serve as a special advisor to the company's global head of R&D to assist in a smooth transition of the new Chief Medical Officer of Immuno-Oncology during the initial period of his appointment until June 30, 2022
.
On February 7, Xinlitai announced that the company recently received a written resignation report submitted by Zhu Meixia, the company's deputy general manager
.
Zhu Meixia applied to resign from the position of deputy general manager of the company because she had reached the retirement age
.
After the resignation takes effect, he will no longer hold any position in the company
.
.
.
.
The above is just a list of some pharmaceutical companies that have undergone personnel changes since February, but on the whole, a large number of pharmaceutical companies in the industry are currently announcing personnel adjustment plans under pressure from various aspects, reducing non-core business personnel, in order to save development funds, Adjust the development strategy
.
The analysis believes that this is the case for large pharmaceutical companies, and the funds of small pharmaceutical companies are more tight, so personnel reduction may be more frequent in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
